Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2013 Jul 13

PMID 23847057

Citations 41

Authors

Tae-Wook Chun

J Shawn Justement

Danielle Murray

Connie J Kim

Jana Blazkova

Claire W Hallahan

Erika Benko

Cecilia T Costiniuk

Gabor Kandel

Mario Ostrowski

Rupert Kaul

Susan Moir

Joseph P Casazza

Richard A Koup

Colin Kovacs

Anthony S Fauci

Affiliations

Soon will be listed here.

Abstract

Elite controllers suppress human immunodeficiency virus (HIV) viremia to below the limit of detection in the absence of antiretroviral therapy (ART). However, precise frequencies of CD4(+) T cells carrying replication-competent HIV and/or the dynamics of the infectious viral reservoirs in response to initiation and discontinuation of ART in elite controllers are unknown. We show that the size of the pool of CD4(+) T cells harboring infectious HIV diminished significantly after initiation of ART and rebounded to baseline upon cessation of therapy. Our data provide compelling evidence that persistent viral replication occurs in untreated elite controllers even in the absence of detectable plasma viremia.

Citing Articles

Persistent elite controllers as the key model to identify permanent HIV remission.

Gasca-Capote C, Ruiz-Mateos E Curr Opin HIV AIDS. 2025; 20(2):165-171.

PMID: 39773856 PMC: 11809733. DOI: 10.1097/COH.0000000000000907.

Inhibition of HIV-1 release by ADAM metalloproteinase inhibitors.

Ireland J, Segura J, Shi G, Buchwald J, Roth G, Shen T Front Microbiol. 2024; 15:1385775.

PMID: 38572241 PMC: 10987949. DOI: 10.3389/fmicb.2024.1385775.

Ongoing HIV-1 evolution and reservoir reseeding in two elite controllers with genetically diverse peripheral proviral quasispecies.

de Azevedo S, Cortes F, Villela L, Hoagland B, Grinsztejn B, Veloso V Mem Inst Oswaldo Cruz. 2023; 118:e230066.

PMID: 37283423 PMC: 10292822. DOI: 10.1590/0074-02760230066.

HIV-1 release requires Nef-induced caspase activation.

Segura J, Ireland J, Zou Z, Roth G, Buchwald J, Shen T PLoS One. 2023; 18(2):e0281087.

PMID: 36780482 PMC: 9925082. DOI: 10.1371/journal.pone.0281087.

Comprehensive analysis of HIV reservoirs in elite controllers.

Kennedy B, Blazkova J, Justement J, Shi V, Rai M, Manning M J Clin Invest. 2023; 133(3).

PMID: 36719383 PMC: 9888367. DOI: 10.1172/JCI165446.

References

Madec Y, Boufassa F, Porter K, Meyer L . Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS. 2005; 19(17):2001-7. DOI: 10.1097/01.aids.0000194134.28135.cd. View

Carrington M, Walker B . Immunogenetics of spontaneous control of HIV. Annu Rev Med. 2012; 63:131-45. PMC: 3725592. DOI: 10.1146/annurev-med-062909-130018. View

Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J . HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol. 2010; 84(24):12971-81. PMC: 3004307. DOI: 10.1128/JVI.00387-10. View

Yukl S, Shergill A, McQuaid K, Gianella S, Lampiris H, Hare C . Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010; 24(16):2451-60. PMC: 2997807. DOI: 10.1097/QAD.0b013e32833ef7bb. View

Hatano H, Delwart E, Norris P, Lee T, Dunn-Williams J, Hunt P . Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2008; 83(1):329-35. PMC: 2612329. DOI: 10.1128/JVI.01763-08. View

OConnell K, Brennan T, Bailey J, Ray S, Siliciano R, Blankson J . Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol. 2010; 84(14):7018-28. PMC: 2898225. DOI: 10.1128/JVI.00548-10. View

Okulicz J, Grandits G, Weintrob A, Landrum M, Ganesan A, Crum-Cianflone N . CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis. 2010; 50(8):1187-91. DOI: 10.1086/651421. View

Dinoso J, Kim S, Siliciano R, Blankson J . A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008; 47(1):102-4. PMC: 2564994. DOI: 10.1086/588791. View

Deeks S, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N . Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012; 12(8):607-14. PMC: 3595991. DOI: 10.1038/nri3262. View

10.

Pereyra F, Palmer S, Miura T, Block B, Wiegand A, Rothchild A . Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009; 200(6):984-90. PMC: 3725728. DOI: 10.1086/605446. View

11.

Chun T, Justement J, Moir S, Hallahan C, Maenza J, Mullins J . Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007; 195(12):1762-4. DOI: 10.1086/518250. View

12.

Buzon M, Massanella M, Llibre J, Esteve A, Dahl V, Puertas M . HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010; 16(4):460-5. DOI: 10.1038/nm.2111. View

13.

Gandhi R, Zheng L, Bosch R, Chan E, Margolis D, Read S . The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010; 7(8). PMC: 2919424. DOI: 10.1371/journal.pmed.1000321. View

14.

Volberding P, Deeks S . Antiretroviral therapy and management of HIV infection. Lancet. 2010; 376(9734):49-62. DOI: 10.1016/S0140-6736(10)60676-9. View

15.

Sedaghat A, Rastegar D, OConnell K, Dinoso J, Wilke C, Blankson J . T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis. 2009; 49(11):1763-6. PMC: 2783537. DOI: 10.1086/648081. View